Keywords: nordisk, novorapid, gains, ec, clearance, danish, insulin
Nordisk's NovoRapid gains EC clearance
Article | 01 October 2007
Danish insulin giant Novo Nordisk says that the European Commission has approved its rapid-acting insulin product NovoRapid (insulin aspart) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
